Influence of AGTR1 and ABCB1 Gene Polymorphism on the Curative Effect of Irbesartan.

IF 1.9 4区 医学 Q3 PERIPHERAL VASCULAR DISEASE
International Journal of Hypertension Pub Date : 2022-11-09 eCollection Date: 2022-01-01 DOI:10.1155/2022/4278675
Qiao Wang, Lingsen You, Zeyu Li, Leiyi Zhang, Xueqi Li, Xuesong Yang
{"title":"Influence of AGTR1 and ABCB1 Gene Polymorphism on the Curative Effect of Irbesartan.","authors":"Qiao Wang,&nbsp;Lingsen You,&nbsp;Zeyu Li,&nbsp;Leiyi Zhang,&nbsp;Xueqi Li,&nbsp;Xuesong Yang","doi":"10.1155/2022/4278675","DOIUrl":null,"url":null,"abstract":"<p><p>The interindividual heterogeneity in response to the antihypertensive effect of irbesartan has received considerable attention because of gene polymorphism. In this study, we investigated the new combinational influences of AGTR1 and ABCB1 gene polymorphism on the therapeutic effect of irbesartan among Chinese hypertensive patients. A total of 353 samples including 168 normal people and 185 hypertensive patients were adopted, and genotypes comprise ABCB1 (CC, CT, and TT) and AGTR1 (AA and AC) in this study. The results of multiple linear regression models showed that no statistically significant differences were observed in blood pressure change following irbesartan administration in each genotype from either ABCB1 (CC, CT, and TT) or AGTR1 (AA and AC). However, spline smoothing analysis demonstrated that the blood pressure therapeutic responses of irbesartan presented a noticeable difference among different ABCB1 genotypes when irbesartan doses reached over 300 ng/mL. Eventually, we assumed that the different drug responses of irbesartan among various AGTR1 genotypes were due to the diversity of the irbesartan-conjugated protein, which is responsible for crossing-coupled intracellular G-protein-coupled receptors (GPCRs).</p>","PeriodicalId":14132,"journal":{"name":"International Journal of Hypertension","volume":" ","pages":"4278675"},"PeriodicalIF":1.9000,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668479/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/4278675","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

The interindividual heterogeneity in response to the antihypertensive effect of irbesartan has received considerable attention because of gene polymorphism. In this study, we investigated the new combinational influences of AGTR1 and ABCB1 gene polymorphism on the therapeutic effect of irbesartan among Chinese hypertensive patients. A total of 353 samples including 168 normal people and 185 hypertensive patients were adopted, and genotypes comprise ABCB1 (CC, CT, and TT) and AGTR1 (AA and AC) in this study. The results of multiple linear regression models showed that no statistically significant differences were observed in blood pressure change following irbesartan administration in each genotype from either ABCB1 (CC, CT, and TT) or AGTR1 (AA and AC). However, spline smoothing analysis demonstrated that the blood pressure therapeutic responses of irbesartan presented a noticeable difference among different ABCB1 genotypes when irbesartan doses reached over 300 ng/mL. Eventually, we assumed that the different drug responses of irbesartan among various AGTR1 genotypes were due to the diversity of the irbesartan-conjugated protein, which is responsible for crossing-coupled intracellular G-protein-coupled receptors (GPCRs).

Abstract Image

Abstract Image

Abstract Image

AGTR1和ABCB1基因多态性对厄贝沙坦疗效的影响。
厄贝沙坦降压效应的个体间异质性由于基因多态性而受到广泛关注。在本研究中,我们研究了AGTR1和ABCB1基因多态性对厄贝沙坦治疗中国高血压患者疗效的新的联合影响。本研究共采用353份样本,包括168名正常人和185名高血压患者,基因型包括ABCB1 (CC、CT和TT)和AGTR1 (AA和AC)。多元线性回归模型的结果显示,无论是ABCB1 (CC、CT和TT)还是AGTR1 (AA和AC),各基因型患者在厄贝沙坦给药后的血压变化均无统计学差异。然而,样条平滑分析表明,当厄贝沙坦剂量超过300 ng/mL时,不同ABCB1基因型对厄贝沙坦的血压治疗效果存在显著差异。最后,我们假设厄贝沙坦在不同AGTR1基因型之间的不同药物反应是由于厄贝沙坦偶联蛋白的多样性,该蛋白负责细胞内g蛋白偶联受体(gpcr)的交叉偶联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Hypertension
International Journal of Hypertension Medicine-Internal Medicine
CiteScore
4.00
自引率
5.30%
发文量
45
期刊介绍: International Journal of Hypertension is a peer-reviewed, Open Access journal that provides a forum for clinicians and basic scientists interested in blood pressure regulation and pathophysiology, as well as treatment and prevention of hypertension. The journal publishes original research articles, review articles, and clinical studies on the etiology and risk factors of hypertension, with a special focus on vascular biology, epidemiology, pediatric hypertension, and hypertensive nephropathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信